Ratings Moves: MGM,...
Health Care: Drugs
Merck & Co Inc (MRK: NYSE)
$47.33 0.62 | 1.33%
05/23/13 - 04:00 PM ET
22.56M / 16.90M
Vol / Avg. Vol:46.46 / 46.71
Open / Prev. Close:46.42 - 47.44
Today's Range:37.02 - 48.79
52 Wk Range:14.09%
Performance YTD:TheStreet Rating:
Portfolios with MRK
- Portfolio NameUser Type
- User2013
- ContributorStocks Rising On Unusual Vo...
- UserJeeper Portfolio 1
- UserCapt Jer
- Userlennyvb Portfolio 1
- ContributorDogs of the Dow 2013
- ContributorTechnical Setups for the We...
- ContributorHigh Volume Technicals for ...
- UserCovered Calls
- Contributor9 Dow Dividend Stocks With ...
Latest MRK Headlines from TheStreet
- Dow Today: Merck (MRK) Leads The Day Higher, International Business Machines (IBM) Lags 05.23.13 | 04:05 pm
- 5 Stocks Raising The Drugs Industry Higher 05.23.13 | 01:05 pm
- Merck & Co Inc (MRK): Today's Featured Drugs Laggard 05.22.13 | 05:05 pm
- Dow Today: Merck (MRK) Higher 05.22.13 | 12:05 pm
- Benefiting From the Rotation To Cyclicals
05.22.13 | 11:05 am - Allocate Assets to Buy-Rated Dow Stocks 05.22.13 | 08:05 am
- Merck Rises On Unusually High Volume (MRK) 05.21.13 | 03:05 pm
- Dow Today: Merck (MRK) Higher 05.21.13 | 12:05 pm
- Cramer's 'Mad Money' Recap: Think Dividends, Not Coupons 05.20.13 | 08:05 pm
- Dow Today: Merck (MRK) Lower 05.17.13 | 12:05 pm
Press Releases for MRK
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet - Business Wire 03.27.13 | 08:03 am
- Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease - Business Wire 03.13.13 | 08:03 am
- Results From HPS2-THRIVE Study Of TREDAPTIVE™ (extended-release Niacin/laropiprant) Presented At American College Of Cardiology Scientific Sessions - Business Wire 03.09.13 | 12:03 pm
- Roger M. Perlmutter (Photo: Business Wire) - Business Wire 03.07.13 | 07:03 am
- Merck To Present At The 33rd Annual Cowen Health Care Conference - Business Wire 03.05.13 | 08:03 am
- Merck Announces Second-Quarter 2013 Dividend - Business Wire 02.26.13 | 02:02 pm
- Merck To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets - Business Wire 02.22.13 | 08:02 am
- Merck And Samsung Bioepis Enter Biosimilars Development And Commercialization Agreement - Business Wire 02.20.13 | 07:02 am
Partner Headlines for MRK
- Companies slide $181B through tax loopholes - MSN Money 04.19.13 | 10:04 am
- Revive leadership in pharma R&D - Financial Times 04.17.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,297.25 up 59.39 points - NASDAQ 04.10.13 | 08:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,218.60 down -36.26 points - NASDAQ 04.03.13 | 08:04 pm
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- New foot-and-mouth vaccine developed - Financial Times 03.27.13 | 11:03 pm
- 'Pay For Delay' Case Could Change Generic Drug Rules - Investor's Business Daily 03.26.13 | 04:03 pm
- Common Sense Says Time For Quality, Dividends And Premiums - Seeking Alpha 03.23.13 | 06:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Looking For Bargains And Safety - Seeking Alpha 03.17.13 | 09:03 am
